化合物简介
Navitoclax (previously ABT-263) is an experimental orally active anti-cancer drug, which is similar in action to obatoclax, except that unlike obatoclax, it does not have off-target effects.
基本信息
中文名称
ABT-263
英文名称
Navitoclax
中文别名
(R)-4-(4-((4\'-氯-4,4-二甲基-3,4,5,6-四氢-[1,1\'-联苯]-2-基)甲基)哌嗪-1-基)-N-((4-((4-吗啉-1-(苯硫基)-2-丁基)氨基)-3-((三氟甲基)磺酰基)苯基)磺酰基)苯甲酰胺
英文别名
ABT263、ABT-263、4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide、(R)-4-(4-((4\'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1\'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
CAS号
923564-51-6
分子式
C47H55ClF3N5O6S3
分子量
974.613
精确质量
973.296
PSA
170.42
LOGP
11.3995
编号系统
UNII
XKJ5VVK2WD
物化性质
外观与性状
淡黄色固体
密度
1.41 g/cm3
熔点
114-116ºC
折射率
1.654
